title: Renal and hormonal effects of systemic nitric oxide inhibition in patients with congestive heart failure and in healthy control subjects.
abstract: BACKGROUND
  The significance of basal renal nitric oxide (NO) availability in the regulation of renal perfusion and sodium excretion in human congestive heart failure (CHF) has not been described previously.
  
  
  RESULTS
  We studied the effects of acute systemic NO synthesis inhibition with N(G)-monomethyl-L-arginine (L-NMMA) in 12 patients with CHF and 10 healthy control subjects (CON) in a randomized placebo-controlled study. Effect parameters were renal plasma flow (RPF), renal vascular resistance (RVR), glomerular filtration rate (GFR), urine sodium excretion and plasma levels of vasoactive hormones. L-NMMA was associated with a significant decrease in RPF (CON-LNMMA: -13 ± 3% [P = .014]; CHF-LNMMA: -17 ± 7% [P = .017]) and a profound increase in RVR in both CHF and CON (CON-LNMMA: +26 ± 6% [P = .009]; CHF-LNMMA: +37 ± 70% [P = .005]). Significant decreases in sodium excretion were found in both CHF-LNMMA and CON-LNMMA. Relative changes from baseline were not statistically different between CHF-LNMMA and CON-LNMMA. After L-NMMA, RPF values correlated inversely with plasma aldosterone in CHF-LNMMA (P = .01). L-NMMA induced an increase in A-type natriuretic peptide (ANP) only in CHF-LNMMA (+18 ± 8%; P = .035), which correlated significantly with basal ANP levels (P = .034).
  
  
  CONCLUSIONS
  There was no difference in the renal response to L-NMMA in CHF vs CON, suggesting that the impact of NO on renal perfusion and sodium excretion is maintained in stable CHF. We suggest that NO influences the release of ANP during high levels of atrial stretch in CHF.
authors.affiliation: Department of Medical Research, Holstebro Hospital, Holstebro, Denmark and Aarhus University, Aarhus, Denmark. Electronic address: jnbech@dadlnet.dk.
authors.forename: J N
authors.initials: JN
authors.lastname: Bech
authors.forename: J
authors.initials: J
authors.lastname: Starklint
authors.forename: H
authors.initials: H
authors.lastname: Bentzen
authors.forename: O
authors.initials: O
authors.lastname: Nyvad
authors.forename: E B
authors.initials: EB
authors.lastname: Pedersen
mesh_terms: D000368:Aged; D000450:Aldosterone / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects / Q000502:physiology*; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy / Q000652:urine; D006801:Humans; D007668:Kidney / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000097:blood* / Q000652:urine; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology*; D019323:omega-N-Methylarginine / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D004791:Enzyme Inhibitors; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D000450:Aldosterone; D009320:Atrial Natriuretic Factor
keywords: ANP; N(G)-monomethyl-L-arginine; Nitric oxide; aldosterone; renal plasma flow